The role and mechanism of endothelial cell-specific molecule-1 in respiratory diseases.
- 1Department of Pulmonary and Critical Care Medicine, First Affiliated Hospital, Kunming Medical University, Kunming, China.
Abstract
Endothelial cell-specific molecule-1 (ESM1) is a soluble dermatan sulfate proteoglycan and is mainly expressed in pulmonary endothelial cells. It is reported that ESM1 plays an important role in promoting cell proliferation, such as metabolic reprogramming, and inhibiting autophagy. In addition, ESM1 exerts a dual regulatory effect on inflammation. However, the mechanism of the dual regulatory effect of ESM1 on inflammation remains unclear. Moreover, evidence suggests that ESM1 is involved in multiple signaling pathways, such as the EGFR/ESM1, EGFR/HER3-Akt/ANGPT2, HGF/c-MET, VEGF-A/ESM1, mTOR, and ZEB1/PI3K/AKT pathways. Increasing studies suggested that ESM1 is involved in various respiratory diseases, such as lung cancer, obstructive sleep apnea hypopnea syndrome (OSAHS), pulmonary arterial hypertension (PAH), and acute lung injury (ALI)/acute respiratory distress syndrome (ARDS). In lung cancer, ESM1 promotes cancer cell proliferation through the EGFR, NF-κB, and HGF/c-MET signaling pathways. In OSAHS, ESM1 enhances inflammatory factor secretion and monocyte-endothelial cell adhesion through the HIF-1α/VEGF signaling pathway. In PAH, ESM1 may promote vascular remodeling and inflammation via a positive feedback loop with TNF-α. Conversely, in ALI/ARDS, ESM1 may inhibit leukocyte recruitment to reduce inflammation. However, the specific roles and mechanisms of ESM1 in chronic obstructive pulmonary disease (COPD), asthma, and pneumonia need to be further explored. Accordingly, ESM1 may serve as a potential therapeutic target for various respiratory diseases.
Related
- Predictors of pulmonary embolism in chronic obstructive pulmonary diseases patients admitted for worsening respiratory symptoms: An individual participant data meta-analyses
- Mimicking in vivo Inflammation: A New in vitro Model of Endothelial Inflammation to Advance the Study of IMID-Associated Cardiovascular Diseases
- MtbAIM: AI/ML-guided endpoint-specific prediction of small-molecule activity across drug-susceptible and drug-resistant Mycobacterium tuberculosis
- Ligand-specific endothelial Notch signaling coordinates brain pericyte specification and expansion
- An endothelial-specific TIE2-L914F mouse model reveals cellular mechanisms of venous malformation progression and recapitulates the patient's response to targeted therapy
BibTeX
@article{huang2026role,
title = {{The role and mechanism of endothelial cell-specific molecule-1 in respiratory diseases.}},
author = {Ling Huang and Xiaofei Liu and Qianbiao Rao and Yingchun Zou and Yiqiong Wen and Talhah Arif and Yuanyuan Zheng and Shibo Sun},
journal = {Frontiers in physiology},
year = {2026},
month = oct,
doi = {10.3389/fphys.2026.1914718},
url = {https://europepmc.org/article/MED/42953564},
note = {CC BY},
}
RIS
TY - JOUR
TI - The role and mechanism of endothelial cell-specific molecule-1 in respiratory diseases.
AU - Ling Huang
AU - Xiaofei Liu
AU - Qianbiao Rao
AU - Yingchun Zou
AU - Yiqiong Wen
AU - Talhah Arif
AU - Yuanyuan Zheng
AU - Shibo Sun
PY - 2026
DA - 2026/10/14
JO - Frontiers in physiology
DO - 10.3389/fphys.2026.1914718
UR - https://europepmc.org/article/MED/42953564
AB - Endothelial cell-specific molecule-1 (ESM1) is a soluble dermatan sulfate proteoglycan and is mainly expressed in pulmonary endothelial cells. It is reported that ESM1 plays an important role in promoting cell proliferation, such as metabolic reprogramming, and inhibiting autophagy. In addition, ESM1 exerts a dual regulatory effect on inflammation. However, the mechanism of the dual regulatory effect of ESM1 on inflammation remains unclear. Moreover, evidence suggests that ESM1 is involved in multiple signaling pathways, such as the EGFR/ESM1, EGFR/HER3-Akt/ANGPT2, HGF/c-MET, VEGF-A/ESM1, mTOR, and ZEB1/PI3K/AKT pathways. Increasing studies suggested that ESM1 is involved in various respiratory diseases, such as lung cancer, obstructive sleep apnea hypopnea syndrome (OSAHS), pulmonary arterial hypertension (PAH), and acute lung injury (ALI)/acute respiratory distress syndrome (ARDS). In lung cancer, ESM1 promotes cancer cell proliferation through the EGFR, NF-κB, and HGF/c-MET signaling pathways. In OSAHS, ESM1 enhances inflammatory factor secretion and monocyte-endothelial cell adhesion through the HIF-1α/VEGF signaling pathway. In PAH, ESM1 may promote vascular remodeling and inflammation via a positive feedback loop with TNF-α. Conversely, in ALI/ARDS, ESM1 may inhibit leukocyte recruitment to reduce inflammation. However, the specific roles and mechanisms of ESM1 in chronic obstructive pulmonary disease (COPD), asthma, and pneumonia need to be further explored. Accordingly, ESM1 may serve as a potential therapeutic target for various respiratory diseases.
SN - 1664-042X
ER -